Work Productivity and Activity Impairment Among Chronic Spontaneous/Idiopathic Urticaria Patients: ResultsFrom The First International Burden of Illness Study (Assure-Csu)-Reference-Cited by-同舟云学术

Work Productivity and Activity Impairment Among Chronic Spontaneous/Idiopathic Urticaria Patients: ResultsFrom The First International Burden of Illness Study (Assure-Csu)

Published:2015-11 Issue:7 Volume:18 Page:A427
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Balp M,Chambenoit O,Chiva-Razavi S,Lynde C,Sussman G,Chapman-Rothe N,Weller K,Maurer M,Koenders J,Knulst AC,Halliday A,Alexopoulos ST,Nakonechna A,Grattan C,Abouzakouk M,Sweeney C,Radder C,Wolin D,McBride D,Hollis K,Tian H,Elberink JN

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with Chronic Urticaria Remain Largely Undertreated: Results from the DERMLINE Online Survey;Dermatology and Therapy;2021-05-04

2. Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H1-Antihistamines in Asia, Middle-East and Africa: Results from the AWARE-AMAC study;World Allergy Organization Journal;2020-04

3. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real‐world study in Belgium;Journal of the European Academy of Dermatology and Venereology;2019-08-19

4. Antihistamine‐resistant chronic spontaneous urticaria: 1‐year data from the AWARE study;Clinical & Experimental Allergy;2018-12-07

5. Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria;British Journal of Dermatology;2018-06-15